Differences between whole body magnetic resonance imaging (WB-MRI) and chest/abdomen/pelvis computed tomography (CT)/bone scan (CT/B) in patients staged as having metastatic hormone-sensitive prostate cancer (mHSPC): A retrospective comparative study within a single trust in the UK.

• DOI: 10.1200/jco.2024.42.4_suppl.37
• Publication Date: 2024-01-29T21:06:41Z
• Authors: Mona Hassan; Shobana Anpalakhan; Akash Maniam; Aruni Ghose; Utku Lokman; Tomasz Olejnik; Giuseppe Luigi Banna
• Keywords: Whole body imaging

37 Background: Diagnostic imaging for metastases detection in HSPC varies across different countries with increasing use of WB-MRI and PSMA-PET. However, CT/B has still been the most used modality real world recent registration clinical trials this disease setting. Methods: We performed a cross-sectional retrospective descriptive study comparing as baseline staging modalities patients diagnosed mHSPC between February 2017 August 2023 two hospitals belonging to same NHS trust UK routinely using one two. The aimed at differences identification metastatic sites CHAARTED volume/LATITUDE risk, relative impact on patients’ received therapies outcomes. Results: Of 213 mHSPC, 121 had WB-MRI, 86 7 choline or PSMA PET. Compared CT/B, staged by were significantly higher bone-only (47 vs 24%, p=0.002) lower lymph-node only (11 27%, p=0.005); high-volume (49 21%, p<0.001) -risk (48 17%, p<0.001); de-novo (91 66%, previously less radical surgery (2 13%, p=0.003) radiotherapy (7 more frequently ADT plus Docetaxel (65 44%, p=0.005). Treatment outcome results overall cohorts’ populations according volume/risk will be presented. Conclusions: In homogenous cohort patients, we found relevant discrepancy high-volume/risk related rate WB-MRI. This may prompt clinicians offer systemic burden could also have role avoiding overtreatments under-staged disease.